This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, eHealth) (354) Breast Cancer (210)

Published on in Vol 8, No 12 (2019): December

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/14339, first published .
An Electronic Health Intervention for Latina Women Undergoing Breast Cancer Treatment (My Guide for Breast Cancer Treatment): Protocol for a Randomized Controlled Trial

An Electronic Health Intervention for Latina Women Undergoing Breast Cancer Treatment (My Guide for Breast Cancer Treatment): Protocol for a Randomized Controlled Trial

An Electronic Health Intervention for Latina Women Undergoing Breast Cancer Treatment (My Guide for Breast Cancer Treatment): Protocol for a Randomized Controlled Trial

Authors of this article:

Betina Yanez1 Author Orcid Image ;   Sharon H Baik2 Author Orcid Image ;   Laura B Oswald2 Author Orcid Image ;   Diana Buitrago2 Author Orcid Image ;   Joanna Buscemi3 Author Orcid Image ;   Francisco Iacobelli4 Author Orcid Image ;   Alejandra Perez-Tamayo5 Author Orcid Image ;   Precilla Fajardo2 Author Orcid Image ;   Gabriela Serrano2 Author Orcid Image ;   Judith Guitelman6 Author Orcid Image ;   Frank J Penedo7 Author Orcid Image
Article Authors Cited by (7) Tweetations (5) Metrics

    Protocol

    1Northwestern University Feinberg School of Medicine, Chicago, IL, United States

    2DePaul University, Chicago, IL, United States

    3Northeastern Illinois University, Chicago, IL, United States

    4University of Illinois at Chicago, Chicago, IL, United States

    5ALAS-WINGS, Chicago, IL, United States

    6University of Miami, Miami, FL, United States

    Corresponding Author:

    Betina Yanez, PhD

    Northwestern University Feinberg School of Medicine

    633 N Saint Clair St

    Chicago, IL, 60611-3234

    United States

    Phone: 1 312 503 5341

    Email: betina.yanez@northwestern.edu


    Background: Among Latinas and Hispanics (henceforth referred to as Latinas), breast cancer is the most commonly diagnosed cancer and the leading cause of cancer-related deaths. However, few interventions have been developed to meet the needs of Latina women undergoing active treatment for breast cancer.

    Objective: This paper aims to describe the procedures and methods of My Guide for Breast Cancer Treatment and the plans for conducting a multisite randomized controlled trial to investigate the feasibility and preliminary efficacy of this smartphone-based app for Latina women in active treatment for breast cancer.

    Methods: Study participants will be randomized to the My Guide for Breast Cancer Treatment intervention or the enhanced usual care control condition for 12 weeks. Participants will have access to innovative features such as gamification via virtual awards to reinforce usage and an adaptive section that presents targeted material based on their self-reported concerns and needs. Using a stepped-care approach, intervention participants will also receive telecoaching to enhance their adherence to the app. Study outcomes and intervention targets will be measured at study enrollment (before randomization), 6 and 12 weeks after initial app use. General and disease-specific health-related quality of life (HRQoL) and symptom burden are the study’s primary outcomes, whereas anxiety, depression, fear of cancer recurrence, physical activity, and dietary intake are secondary outcomes.

    Results: Recruitment began in August 2019 and is expected to be completed by August 2020. We expect to submit study results for publication by fall 2020.

    Conclusions: My Guide for Breast Cancer Treatment has the potential to improve HRQoL and reduce symptom burden, and increase access to supportive care resources among Latina breast cancer patients.

    International Registered Report Identifier (IRRID): PRR1-10.2196/14339

    JMIR Res Protoc 2019;8(12):e14339

    doi:10.2196/14339

    Keywords

    breast cancer; Latina; health-related quality of life; eHealth; randomized controlled trial 


    Background

    Among Latinas/Hispanics (henceforth referred to as Latinas), breast cancer is the most commonly diagnosed cancer and the leading cause of cancer-related deaths [1]. Compared with non-Latina breast cancer survivors (BCSs), Latina BCSs report multiple disparities including poorer health-related quality of life (HRQoL), greater symptom burden, greater cancer-related psychosocial needs [2-4], less breast cancer knowledge, and more dissatisfaction with information related to breast cancer care [5]. Prior studies show that poorer HRQoL is related to lower levels of adherence to disease surveillance and adjuvant treatment [6,7], and interventions designed to improve HRQoL specifically for Latina BCSs can improve adherence to posttreatment care and health outcomes [2,8,9]. However, given the documented disparities beyond HRQoL, interventions targeting Latina BCSs must also provide education about cancer-related symptoms and evidence-based tools to manage symptoms and associated distress.

    Objectives

    To address poor HRQoL among Latina BCSs, our team previously developed and pilot tested My Guide, a smartphone-based app designed specifically for Latina BCSs to improve HRQoL and reduce symptom burden after completing primary breast cancer treatment [10]. The initial My Guide app is available in both English and Spanish, expanding its reach to underserved Latina BCSs. Preliminary findings show that My Guide is feasible for Latina BCSs to use (eg, acceptable app usage and high user satisfaction) [11]. However, many of our participants noted that they wished that they had access to the app content during treatment.

    To date, few interventions have been developed to meet the needs of Latina women undergoing active treatment for breast cancer [12]. There is a critical need for culturally informed interventions designed to address the supportive care needs of Latina women in active treatment, particularly for primarily Spanish-speaking women [3]. Given the high rates of internet and smartphone use documented among US Latinos [13], electronic health–based interventions may capitalize on opportunities to provide scalable resources to Latinas undergoing active treatment while limiting participant burden [14-17].

    In light of the limited technology-assisted interventions specifically designed for Latina women undergoing active treatment for breast cancer, more studies are needed to establish the feasibility of smartphone-based interventions for Latinas during active cancer treatment [12]. In response to the feedback from our participants enrolled in the My Guide pilot study and the dearth of literature regarding interventions for Latina breast cancer patients actively undergoing treatment, we have developed My Guide for Breast Cancer Treatment. The purpose of this paper is to describe the procedures and methods of this follow-up intervention. Guided by Bowen et al’s conceptual model of feasibility studies [18], we describe the plans for conducting a multisite, randomized controlled trial (RCT) to establish the feasibility of My Guide for Breast Cancer Treatment for Latina women undergoing breast cancer treatment.


    Hypotheses

    We hypothesize that Latina women will find My Guide for Breast Cancer Treatment feasible for accessing information related to breast cancer and its treatment and for learning strategies to improve symptom management, self-efficacy, communication, and stress. We also hypothesize that women randomized to the My Guide for Breast Cancer Treatment app will have better primary outcomes (ie, HRQoL) and secondary outcomes (ie, symptom burden, anxiety, depressive symptoms, and distress) than women randomized to an enhanced usual care control condition.

    Study Design

    This RCT is designed to assess the preliminary feasibility and efficacy of the My Guide for Breast Cancer Treatment smartphone app for improving HRQoL and symptom burden in Latina women receiving treatment for primary breast cancer. After providing informed consent, participants will be randomized to the My Guide for Breast Cancer Treatment intervention condition or to the enhanced usual care control condition. Randomization will be stratified by recruitment site and language (ie, English and Spanish). Participants randomized to the My Guide for Breast Cancer Treatment intervention condition will have access to the smartphone app for 12 weeks and will be encouraged to use the app for 1.5 hours each week. The My Guide for Breast Cancer Treatment app is accessible on all smartphones (eg, Apple and Samsung) as well as tablets and computer websites. It is available in both English and Spanish, and participants will be provided the app in their preferred language. Participants randomized to the My Guide for Breast Cancer Treatment intervention condition will be oriented to the app and instructed to use it for 1.5 hours each week for a duration of 12 weeks. A 12-week intervention timeframe was selected based on previous studies indicating benefits in HRQoL and symptom burden outcomes after 10 weeks of behavioral interventions and the expected length of adjuvant treatments [19-21]. Thus, we believe that 12 weeks will allow sufficient time for participants to access and benefit from the My Guide for Breast Cancer Treatment app content. Intervention participants will also be assigned a bilingual telecoach for the duration of the study. Using a stepped-care approach [22], intervention participants will receive weekly telecoaching calls based on their level of adherence to the recommended app usage.

    Study outcomes and intervention targets will be measured at study enrollment and before randomization (T1), 6 weeks postbaseline (T2), and 12 weeks postbaseline (T3). All assessment time points will consist of measures assessing our primary outcomes, intervention targets, and secondary outcomes. In addition, all participants will complete a sociodemographic questionnaire at T1, and participants randomized to the intervention condition will be asked to complete an exit survey at T3. Assessments are estimated to take approximately 35 min to complete. Participants randomized to the intervention condition will also be asked to complete brief, 3-min, weekly questionnaires throughout the course of the 12-week intervention. See section Data Collection and Outcomes for greater detail. Participants will be compensated US $100 for their participation in the study and receive partial reimbursement for telephone data usage plans. Participants without an internet-enabled device will be provided one for the duration of the study. All study procedures and assessments have been approved by the institutional review board (IRB) of record for this multisite study (Northwestern IRB).

    Participants

    Participants will be 60 Latina women who have been diagnosed with stage I-IIIA breast cancer, have completed surgery (eg, mastectomy and lumpectomy), and are actively receiving adjuvant treatment for breast cancer (eg, chemotherapy, radiation, and biologic therapy). We will enroll participants from the Robert H. Lurie Comprehensive Cancer Center at Northwestern Memorial Hospital, the University of Illinois Health System, and various community-based support groups sponsored by ALAS-WINGS, a Chicago-based nonprofit organization for Latina breast cancer patients.

    Eligibility

    We will identify participants through screening of the electronic medical record (EMR), and final determinations for study eligibility will be made based on a self-report questionnaire via telephone interview. To be included in the study, participants must (1) be female, because male breast cancer patients represent less than 1% of the breast cancer cases; (2) have a diagnosis of stage I-IIIA breast cancer; (3) have completed surgery for breast cancer; (4) be within any timepoint of the adjuvant treatment trajectory for breast cancer (eg, chemotherapy, radiation, surgery, and biologic therapy); (5) be at least 18 years of age; (6) be able to speak and read English or Spanish; (7) be able to provide informed consent; and (8) self-identify as Hispanic/Latina ethnicity. Participants will be excluded from the study if they (1) have a hearing, motor, visual, or voice impairment that would preclude completion of study procedures; (2) have been diagnosed with a psychotic disorder, bipolar disorder, dissociative disorder, or any other diagnosis for which study participation would be inappropriate or dangerous; (3) endorse suicidal ideation, plan, or intent; (4) endorse illicit substance or alcohol dependence; or (5) have been diagnosed with dementia. Patients with metastatic disease will not be included in this study, as they have more extensive treatment regimens and substantially different needs relative to patients with earlier stages of breast cancer.

    Randomization

    Eligible participants who provide informed consent will be individually randomized using a 1:1 ratio to either the intervention condition (My Guide for Breast Cancer Treatment) or the control condition (enhanced usual care) for a total of 3 months.

    Study Conditions and Delivery

    My Guide for Breast Cancer Treatment Development and Content

    My Guide was initially designed to improve HRQoL and reduce symptom burden among Latina BCSs (ie, BCSs who have completed active treatment) [10]. My Guide for Breast Cancer Treatment has been adapted from My Guide to expand its reach to Latina women in active treatment for breast cancer. The My Guide app incorporates elements in the published literature on symptom management in breast cancer literature and investigators with ample clinical expertise and experience conducting behavioral and symptom management research with Hispanic BCSs. The content for both iterations of the intervention were informed by models of stress and coping, cognitive behavioral stress management [23-25], the extant literature related to psychosocial adaptation to breast cancer [26-28], and studies evaluating these models and skills among Latina BCSs [8,9,26,27,29-31]. My Guide and My Guide for Breast Cancer Treatment are culturally informed by Latina values and beliefs including familism, fatalism, external locus of control, and culturally shaped gender roles (ie, Machismo and Marianismo) [30,32,33]. In addition, they both address challenges that may disproportionally affect Latina women, such as language barriers and concerns related to citizenship. In addition, to address low literacy concerns, all the intervention content is accessible through an audio format that is embedded within each app.

    My Guide for Breast Cancer Treatment expands the scope and focus of the intervention by including additional content specifically for women in active treatment. In addition, My Guide for Breast Cancer Treatment includes content related to diet, physical activity, and general health information for breast cancer patients. The My Guide for Breast Cancer Treatment intervention content is organized into 6 modules as described in Table 1, which include content related to breast cancer education (eg, disease-related information and common breast cancer treatments); common physical, psychological, and emotional symptoms women may experience during and after breast cancer treatment; changes to daily life (eg, responsibilities at work and home and relationships with close family and friends); and local community resources for Latinas with breast cancer. In addition, for easy reference, videos and audio recordings from all the sections are listed and organized by topic in the last module (Listen and Learn).

    All intervention participants will be assigned a trained, bilingual telecoach who will provide telecoaching using a stepped-care approach (Figure 1) to enhance adherence to the recommended My Guide for Breast Cancer Treatment app usage. In a given week, participants who use the app for less than 1 hour will be considered nonadherent to the recommended app usage and will receive a telecoaching call. Participants who use the app for 1 hour or more will be considered adherent to the recommended usage and will not receive a telecoaching call. Rather, adherent participants will receive a reinforcing SMS text message. The 1-hour cut-off was based on data from the previous My Guide trial for cancer survivors in which participants’ average use of the study app exceeded 1 hour per week [10].

    Table 1. My Guide for Breast Cancer Treatment main content modules.
    ModuleDescription of information providedExamples
    Managing My SymptomsCommon physical and psychological symptoms patients experience during and after cancer treatmentNausea and vomiting, fatigue, lymphedema, sadness, worry
    Managing My EmotionsEmotions commonly experienced during and after cancer treatmentAnger, anxiety, sadness/depression; improving thoughts and feelings; expressing your feelings
    Understanding Your Breast CancerBreast cancer, adjuvant cancer treatments and related side effectsBreast cancer and treatments overview; following doctor recommendations
    Living Well After TreatmentMaintaining a healthy lifestyle during treatmentDiet and physical activity content specific for patients with cancer
    Friends and FamilyChanges in roles and responsibilities at home and work, relationships with family and friends, and daily activities during and after cancer treatmentChanges to relationships, sexual/intimacy, and at work; advice for singles; talking to your doctor
    Community and Everyday SupportLocal community organizations and resources for Latinas in the Chicagoland area for additional supportSpanish support groups, transportation assistance, financial assistance
    ‎
    Figure 1. Telecoaching stepped-care protocol.
    View this figure

    The telecoaching calls will be brief (15 min) and focus on encouraging adherence to My Guide for Breast Cancer Treatment using the principles of motivational interviewing [34]. During the first call, participants will complete a decisional balance exercise with their telecoach to identify and address potential ambivalence about using the app for the recommended time. Guided by the telecoach, participants will set weekly goals regarding their app usage for the upcoming week, which will be reviewed in subsequent telecoaching calls. A central topic of the telecoaching calls will be barriers and facilitators to app usage, allowing telecoaches to problem solve with participants and set future app usage goals. Importantly, the goal of telecoaching calls is not to deliver intervention content but rather to facilitate adherence to the My Guide for Breast Cancer Treatment app.

    All telecoaches will receive training in motivational interviewing and goal setting with a particular focus on sensitivity to issues relevant for Latina women (eg, cultural beliefs that may influence coping and health behaviors). Telecoaches will have access to participants’ app usage through a study administrative site. All telecoaching calls will be audio-recorded, and approximately 20% of the telecoaching calls will be reviewed weekly in supervision with a licensed clinical psychologist to monitor intervention fidelity.

    One of the most significant additions to the intervention app is that My Guide for Breast Cancer Treatment will be individually tailored to each participant’s self-reported primary concerns/symptoms. Upon randomization, participants in the intervention condition will complete a questionnaire based on the MD Anderson Symptom Inventory [35] to assess for common breast cancer and breast cancer treatment–related concerns, complaints, and symptoms. My Guide for Breast Cancer Treatment will then organize the app presentation such that content related to each participant’s 3 to 5 top-rated concerns/symptoms are most easily accessible in a separate tab titled “Just for Me.” Participants will complete this questionnaire every 2 weeks, with subsequent content-related changes made to their “Just for Me” tab. As tailored information is added to this tab, the most recent additions will appear at the top of this tab, and older content will move to the bottom. Notably, participants will still have access to all of the intervention content. However, this adaptive feature will help participants focus on and prioritize their primary concerns and needs.

    Each week participants will be incrementally rewarded/reinforced for the time spent using the My Guide for Breast Cancer Treatment app. Gamification is use of game-design elements to engage and motivate individuals to achieve a goal [18]. Although the gamification features are becoming increasingly popular in behavioral and medical interventions, only a few studies have demonstrated their potential effectiveness [36-38]. My Guide for Breast Cancer Treatment contains 3 levels of virtual reinforcement in a given week. Participants may receive a virtual ribbon after completing 30 min of app use, a virtual medal after completing 45 min of app use, and a virtual trophy after completing 60 min of app use. Therefore, participants who use the app for a full hour each week for the length of the study can receive a total of 12 ribbons, 12 medals, and 12 trophies [39].

    The smartphone app for the My Guide for Breast Cancer Treatment intervention condition is currently in development with Bright Outcomes Company (see Figure 2).

    ‎
    Figure 2. Screenshot of the My Guide smartphone app.
    View this figure

    Participants will be able to securely log in to the app, and participant usage and engagement with video/audio features will be captured and sent to a secure and Health Insurance Portability and Accountability Act–compliant medical school server housed at Bright Outcomes. Security measures to protect privacy threats associated with users’ computers and devices include the following measures: users are automatically logged out of intervention and assessment tools after 20 min of inactivity; any data stored locally are automatically encrypted based on the user authentication information and cannot be accessed without this information; all information collected by the app will be immediately transmitted to the secure server; and no app data will be saved to the phone’s memory.

    Participants randomized to the enhanced usual care control condition will receive care as usual and printed educational materials from the National Cancer Institute related to breast cancer and survivorship [40], patient education in either English or Spanish, as well as a list of Chicago-based supportive care resources and organizations. They will not receive a smartphone app or telecoaching during the study. Participants randomized to the control condition will be given access to the My Guide for Breast Cancer Treatment app after completing the T3 assessment, a period of 3 months.

    Data Collection and Outcomes

    Consistent with past research, the feasibility of My Guide for Breast Cancer Treatment intervention will be evaluated by assessing the acceptability and demand of the app [18]. Acceptability of the app will be assessed at T3 using a previously tested app satisfaction questionnaire [20] that measures the usefulness, satisfaction, learnability, and usability of My Guide for Breast Cancer Treatment. Above average scores will be considered acceptable. Demand will be measured with study recruitment, retention, and participant use of My Guide for Breast Cancer Treatment (eg, frequency of log-ins, time spent using the app, and content accessed). Recruitment and retention rates of 70% or more will be considered acceptable based on our prior work and published studies [20,41,42].

    All measures will be administered in each participant’s preferred language. For assessments completed in Spanish, we will use measures that have either been previously translated to Spanish and validated or measures that were translated to Spanish for this study by IRB-approved translators.

    Participants will complete a self-report sociodemographic questionnaire at T1 including questions related to age, racial background, Latina ancestry, income, employment, relationship status, educational attainment, years living in the United States, and subjective social status using the MacArthur scale [43]. Participants will self-report clinical information including time since breast cancer diagnosis and surgery, stage of diagnosis, type of surgery, current treatment regimen (eg, chemotherapy and radiation), additional medications, medical comorbidities (assessed using the Charlson Comorbidity Index [44]), and past or current psychiatric diagnoses. Financial toxicity will be measured using Comprehensive Score for financial Toxicity-Functional Assessment of Chronic Illness Therapy [45]. All self-reported medical- and disease-related information will be verified via medical chart review.

    Health-Related Quality of Life

    At T1 to T3, participants will complete the Functional Assessment of Cancer Therapy-Breast (FACT-B). The FACT-B has been extensively used among breast cancer patients [46,47] and measures physical, emotional, social, and functional well-being, as well as breast cancer–related concerns over the past 7 days using a 5-point response scale [46]. Participants randomized to the My Guide for Breast Cancer Treatment intervention condition will also complete the rapid version of the Functional Assessment of Cancer Therapy-General (FACT-G7) on their smartphones every week throughout the 12-week intervention. The FACT-G7 assesses the most prominent HRQoL concerns among cancer patients and is both valid and reliable [48]. The FACT-G7 takes approximately 5 min to complete and is therefore an ideal brief measure of HRQoL to include in a smartphone-delivered intervention.

    Symptom Burden

    At T1 to T3, participants will complete the Breast Cancer Prevention Trial (BCPT) symptom questionnaire. The BCPT is a 25-item questionnaire that asks participants to use a 5-point response scale to rate their level of discomfort with common breast cancer–related symptoms during the past 4 weeks [49].

    Anxiety and Depression

    Anxiety and depressive symptoms will be measured at T1 to T3 using the Patient-Reported Outcomes Measurement Information System (PROMIS) [50,51] via brief computer adaptive tests (CATs). With CATs, participants’ responses guide the system’s choice of subsequent items from a bank of 29 items for anxiety and 28 items for depression.

    Fear of Cancer Recurrence

    At T1 to T3, participants will complete the Concerns About Recurrence Scale to assess fears about breast cancer recurrence [52]. Items address numerous life domains that could be impacted by a breast cancer recurrence, such as physical health and relationships. Participants are asked to use a 5-point response scale to indicate the extent to which they felt threatened by a recurrence in each domain.

    Physical Activity

    Physical activity will be measured at T1 to T3 using the International Physical Activity Questionnaire (IPAQ)-short form [53,54]. This measure consists of 7 items that assess physical activity over the past 7 days, and participants record the number of days per week or minutes per day spent doing specific activities. Previous reviews have demonstrated that the IPAQ-short form has high reliability [55,56], and the test-retest reliability of the questionnaire was at an acceptable level [55].

    Dietary Intake

    Dietary intake will be measured at T1 to T3 using the Brief Dietary Assessment Tool for Latinas [57]. This screening tool assesses fruit, vegetable, and fat intake over the past month.

    Self-Efficacy

    A total of 3 self-report questionnaires will be used to measure cancer-relevant self-efficacy at T1 to T3. First, the Communication and Attitudinal Self-Efficacy scale for cancer (CASE-cancer) is a psychometrically valid 12-item measure. A total of 2 CASE-cancer subscales will be used to assess a person with cancer’s self-efficacy in communication and information seeking [58]. Participants rate their level of confidence related to 12 skills using a 4-point response scale. This measure has been previously used with Latina BCSs [58,59]. Second, the PROMIS Self-Efficacy for Managing Emotions CAT will be administered, which assesses a person’s level of confidence to (1) manage symptoms of anger, anxiety, depression, disappointment, discouragement, frustration, and helplessness and (2) prevent symptoms from interfering with daily activities [60]. This measure has an item bank of 25 items. Finally, the 3-item “Assertiveness” scale from the Measure of Current Status will be used to assess a participant’s degree of confidence about asking and expressing their needs [61]. 

    Breast Cancer Treatment Knowledge

    The Knowledge about Breast Cancer questionnaire will be used to assess knowledge related to treatment at T1 to T3. This scale consists of 16 true or false statements regarding general breast cancer knowledge. The average number of correct responses will be calculated. This questionnaire was previously tested with a large sample of Spanish-speaking Latina BCSs [62] and used in the initial My Guide pilot study [10].

    Cancer-Specific Distress

    The Impact of Events Scale will be used to assess cancer-specific distress at T1 to T3. This measure comprises 2 subscales assessing the frequency of intrusive thoughts and avoidance following a stressful event [63,64].

    Analytic Plan

    Descriptive statistics will be used to characterize the overall sample, each condition, and study acceptability and demand. To examine preliminary differences in feasibility between study conditions, we will use the chi-square test, Fisher exact test, and nonparametric Mann-Whitney U test for non-normal data, as appropriate. With 30 participants per study condition, there will be 80% power to detect approximately one-half SDs, assuming a 2-tailed test and a type I error rate of 5%. All power calculations were run using PROC POWER in SAS version 9.4.

    For each study outcome, average changes from pre intervention to post intervention will be calculated via means (SD) and 95% CIs, and the mean changes within study condition will be converted to effect sizes. An analysis of covariance approach will be used to examine differences between the intervention and control conditions in follow-up scores, after adjusting for baseline score. Established cut-offs will also be referenced for clinically meaningful differences for the FACT-B and FACT-B subscales to identify ranges and patterns of changes in scores across conditions from baseline to follow-up.

    Data Management

    All study data will be managed and stored in Research Electronic Data Capture (REDCap), a secure Web-based research data management system hosted at Northwestern University. All IRB-approved research team members will have access to REDCap. REDCap will be used to organize EMR data and to administer all study questionnaires. The My Guide for Breast Cancer Treatment administrative interface will capture participants’ app usage and weekly questionnaire data, which will be uploaded to REDCap to centralize all research information. Once all data are collected, the data will be imported into SPSS for data cleaning and analysis.


    Recruitment began in July 2019 and is expected to be completed by August 2020. We expect to submit study results for publication by fall 2020.


    Overview

    The aim of the My Guide for Breast Cancer Treatment study is to improve HRQoL and reduce symptom burden among Latina women undergoing active treatment for breast cancer. To the best of our knowledge, this is the first bilingual, smartphone-based supportive care app for Latinas women with breast cancer in active treatment. Providing a supportive and behavioral intervention that focuses on cancer treatment education and self-management during active treatment has the potential to improve patient-reported outcomes and clinical outcomes during active treatment and into survivorship.

    Compared with the first version of the My Guide smartphone app, our team implemented substantial changes in this version of the My Guide for Breast Cancer Treatment app. Adding an adaptive functionality offers My Guide for Breast Cancer Treatment users a more personalized approach to delivering the intervention content, and the addition of a gamification via virtual ribbons, medals, and trophies provides users with encouragement to sustain use of the app across the length of the study. Unlike our first My Guide study [10] that included a 2-month longitudinal trial, we have extended the time frame of this study to 3 months to accommodate the expected time frame during which our study participants will be receiving adjuvant treatment. These strategic changes make this version of the My Guide for Breast Cancer Treatment app and this study design better suited for women in active treatment.

    Limitations

    A few limitations of the study protocol warrant discussion. First, because the focus of this study is on breast cancer patients who are in active treatment, long-term cancer survivors will not be enrolled in this study, which limits study generalizability. In addition, women who are preparing for surgery will not be included in this study. However, My Guide for Breast Cancer Treatment does include a focus on the postsurgical recovery phase such as information related to postsurgical symptoms (eg, pain and lymphedema) and information related to reconstructive surgery.

    Future Directions

    There are several areas for future directions. If found feasible, future studies should establish the efficacy of My Guide for Breast Cancer Treatment across a nation-wide, heterogeneous sample of Latina women diagnosed with breast cancer. Currently, the My Guide for Breast Cancer Treatment app does not include any social media aspects; the potential benefit of adding a social media component to My Guide for Breast Cancer Treatment may be another important direction for future iterations of the app. In addition, given the multiple components of this feasibility trial (ie, app, telecoaching, and SMS text messaging), another important future direction will be to disentangle the effects of each component of the intervention on study outcomes.

    Findings from this second study of the My Guide for Breast Cancer Treatment app are expected to contribute to the literature by establishing the efficacy of a smartphone-delivered intervention to enhance self-management during breast cancer treatment for improving HRQoL and symptom burden among Latina patients. Given the technology-based delivery of this app, the My Guide for Breast Cancer Treatment app has the potential for nation-wide scalability and therefore can increase access to supportive care resources among Latina breast cancer patients.

    Conflicts of Interest

    None declared.

    ‎
    Multimedia Appendix 1

    Peer-reviewer report from the Chicago Cancer Health Equity Collaborative.

    PDF File (Adobe PDF File), 608 KB
    1. American Cancer Society. Cancer Facts & Figures for Hispanics/Latinos 2018-2020.   URL: https:/​/www.​cancer.org/​content/​dam/​cancer-org/​research/​cancer-facts-and-statistics/​cancer-facts-and-figures-for-hispanics-and-latinos/​cancer-facts-and-figures-for-hispanics-and-latinos-2018-2020.​pdf [accessed 2019-07-14]
    2. Luckett T, Goldstein D, Butow PN, Gebski V, Aldridge LJ, McGrane J, et al. Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2011 Dec;12(13):1240-1248. [CrossRef] [Medline]
    3. Moadel AB, Morgan C, Dutcher J. Psychosocial needs assessment among an underserved, ethnically diverse cancer patient population. Cancer 2007 Jan 15;109(2 Suppl):446-454 [FREE Full text] [CrossRef] [Medline]
    4. Yanez B, Thompson EH, Stanton AL. Quality of life among Latina breast cancer patients: a systematic review of the literature. J Cancer Surviv 2011 Jun;5(2):191-207 [FREE Full text] [CrossRef] [Medline]
    5. Olagunju TO, Liu Y, Liang L, Stomber JM, Griggs JJ, Ganz PA, et al. Disparities in the survivorship experience among Latina survivors of breast cancer. Cancer 2018 Jun 1;124(11):2373-2380 [FREE Full text] [CrossRef] [Medline]
    6. Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med 2010 Nov;40(11):1797-1810 [FREE Full text] [CrossRef] [Medline]
    7. Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 2009 Nov 15;115(22):5349-5361 [FREE Full text] [CrossRef] [Medline]
    8. Ashing-Giwa KT. The contextual model of HRQoL: a paradigm for expanding the HRQoL framework. Qual Life Res 2005 Mar;14(2):297-307. [CrossRef] [Medline]
    9. Ashing-Giwa KT, Tejero JS, Kim J, Padilla GV, Hellemann G. Examining predictive models of HRQOL in a population-based, multiethnic sample of women with breast carcinoma. Qual Life Res 2007 Apr;16(3):413-428. [CrossRef] [Medline]
    10. Yanez BR, Buitrago D, Buscemi J, Iacobelli F, Adler RF, Corden ME, et al. Study design and protocol for My Guide: An e-health intervention to improve patient-centered outcomes among Hispanic breast cancer survivors. Contemp Clin Trials 2018 Feb;65:61-68 [FREE Full text] [CrossRef] [Medline]
    11. Buscemi J, Buitrago D, Iacobelli F, Penedo F, Maciel C, Guitleman J, et al. Feasibility of a Smartphone-based pilot intervention for Hispanic breast cancer survivors: a brief report. Transl Behav Med 2018 Jul 7. [CrossRef] [Medline]
    12. Molina Y, Thompson B, Espinoza N, Ceballos R. Breast cancer interventions serving US-based Latinas: current approaches and directions. Womens Health (Lond) 2013 Jul;9(4):335-48; quiz 349 [FREE Full text] [CrossRef] [Medline]
    13. Lopez MH, Gonzalez-Barrera A, Patten E. Pew Research Center. 2013. Closing the Digital Divide: Latinos and Technology Adoption.   URL: https:/​/www.​pewresearch.org/​hispanic/​2013/​03/​07/​closing-the-digital-divide-latinos-and-technology-adoption/​ [accessed 2018-05-10]
    14. Badger TA, Segrin C, Hepworth JT, Pasvogel A, Weihs K, Lopez AM. Telephone-delivered health education and interpersonal counseling improve quality of life for Latinas with breast cancer and their supportive partners. Psychooncology 2013 May;22(5):1035-1042. [CrossRef] [Medline]
    15. Tarver WL, Haggstrom DA. The use of cancer-specific patient-centered technologies among underserved populations in the United States: systematic review. J Med Internet Res 2019 Apr 23;21(4):e10256 [FREE Full text] [CrossRef] [Medline]
    16. Nápoles AM, Santoyo-Olsson J, Chacón L, Stewart AL, Dixit N, Ortiz C. Feasibility of a mobile phone app and telephone coaching survivorship care planning program among Spanish-speaking breast cancer survivors. JMIR Cancer 2019 Jul 9;5(2):e13543 [FREE Full text] [CrossRef] [Medline]
    17. Banas JR, Victorson D, Gutierrez S, Cordero E, Guitleman J, Haas N. Developing a peer-to-peer mHealth application to connect hispanic cancer patients. J Cancer Educ 2017 Mar;32(1):158-165. [CrossRef] [Medline]
    18. Bowen DJ, Kreuter M, Spring B, Cofta-Woerpel L, Linnan L, Weiner D, et al. How we design feasibility studies. Am J Prev Med 2009 May;36(5):452-457 [FREE Full text] [CrossRef] [Medline]
    19. Wagner LI, Duffecy J, Penedo F, Mohr DC, Cella D. Coping strategies tailored to the management of fear of recurrence and adaptation for E-health delivery: The FoRtitude intervention. Cancer 2017 May 15;123(6):906-910 [FREE Full text] [CrossRef] [Medline]
    20. Yanez B, McGinty HL, Mohr DC, Begale MJ, Dahn JR, Flury SC, et al. Feasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancer. Cancer 2015 Dec 15;121(24):4407-4415 [FREE Full text] [CrossRef] [Medline]
    21. Antoni MH, Lechner SC, Kazi A, Wimberly SR, Sifre T, Urcuyo KR, et al. How stress management improves quality of life after treatment for breast cancer. J Consult Clin Psychol 2006 Dec;74(6):1143-1152 [FREE Full text] [CrossRef] [Medline]
    22. Bowen DJ, Kreuter M, Spring B, Cofta-Woerpel L, Linnan L, Weiner D, et al. How We Design Feasibility Studies. American Journal of Preventive Medicine 2009 May;36(5):452-457. [CrossRef]
    23. Lazarus RS, Folkman S. Transactional theory and research on emotions and coping. Eur J Pers 1987;1(3):141-169. [CrossRef]
    24. Penedo FJ, Molton I, Dahn JR, Shen B, Kinsinger D, Traeger L, et al. A randomized clinical trial of group-based cognitive-behavioral stress management in localized prostate cancer: development of stress management skills improves quality of life and benefit finding. Ann Behav Med 2006 Jun;31(3):261-270. [CrossRef] [Medline]
    25. Yanez B, McGinty HL, Buitrago D, Ramirez AG, Penedo FJ. Cancer outcomes in Hispanics/Latinos in the United States: an integrative review and conceptual model of determinants of health. J Lat Psychol 2016 May;4(2):114-129 [FREE Full text] [CrossRef] [Medline]
    26. Graves KD, Jensen RE, Cañar J, Perret-Gentil M, Leventhal K, Gonzalez F, et al. Through the lens of culture: quality of life among Latina breast cancer survivors. Breast Cancer Res Treat 2012 Nov;136(2):603-613 [FREE Full text] [CrossRef] [Medline]
    27. Ganz PA, Kwan L, Stanton AL, Bower JE, Belin TR. Physical and psychosocial recovery in the year after primary treatment of breast cancer. J Clin Oncol 2011 Mar 20;29(9):1101-1109 [FREE Full text] [CrossRef] [Medline]
    28. Stanton AL, Snider PR. Coping with a breast cancer diagnosis: a prospective study. Health Psychol 1993 Jan;12(1):16-23. [CrossRef] [Medline]
    29. Ashing-Giwa KT, Padilla GV, Bohórquez DE, Tejero JS, Garcia M. Understanding the breast cancer experience of Latina women. J Psychosoc Oncol 2006;24(3):19-52. [CrossRef] [Medline]
    30. Nápoles-Springer AM, Ortíz C, O'Brien H, Díaz-Méndez M. Developing a culturally competent peer support intervention for Spanish-speaking Latinas with breast cancer. J Immigr Minor Health 2009 Aug;11(4):268-280 [FREE Full text] [CrossRef] [Medline]
    31. Yanez B, Maggard Gibbons M, Moreno PI, Jorge A, Stanton AL. Predictors of psychological outcomes in a longitudinal study of Latina breast cancer survivors. Psychol Health 2016 Nov;31(11):1359-1374. [CrossRef] [Medline]
    32. Gallo L, Penedo FJ, Monteros K, Arguelles W. Resiliency in the face of disadvantage: do Hispanic cultural characteristics protect health outcomes? J Pers 2009 Dec;77(6):1707-1746. [CrossRef] [Medline]
    33. Interian A, Díaz-Martínez AM. Considerations for culturally competent cognitive-behavioral therapy for depression with hispanic patients. Cogn Behav Pract 2007;14(1):84-97. [CrossRef]
    34. Miller WR, Rollnick S. Motivational Interviewing: Helping People Change. New York: Guilford Press; 2012.
    35. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the MD Anderson Symptom Inventory. Cancer 2000 Oct 1;89(7):1634-1646. [CrossRef] [Medline]
    36. Theng Y, Lee JW, Patinadan PV, Foo SS. The use of videogames, gamification, and virtual environments in the self-management of diabetes: a systematic review of evidence. Games Health J 2015 Oct;4(5):352-361. [CrossRef] [Medline]
    37. Allam A, Kostova Z, Nakamoto K, Schulz PJ. The effect of social support features and gamification on a web-based intervention for rheumatoid arthritis patients: randomized controlled trial. J Med Internet Res 2015 Jan 9;17(1):e14 [FREE Full text] [CrossRef] [Medline]
    38. Kawachi I. It's all in the game-the uses of gamification to motivate behavior change. JAMA Intern Med 2017 Nov 1;177(11):1593-1594. [CrossRef] [Medline]
    39. Li J, Theng Y, Foo S. Game-based digital interventions for depression therapy: a systematic review and meta-analysis. Cyberpsychol Behav Soc Netw 2014 Aug;17(8):519-527 [FREE Full text] [CrossRef] [Medline]
    40. National Cancer Institute. 2018. Facing Forward: Life After Cancer Treatment.   URL: https://www.cancer.gov/publications/patient-education/life-after-treatment.pdf [accessed 2018-06-19]
    41. Campbell LC, Keefe FJ, Scipio C, McKee DC, Edwards CL, Herman SH, et al. Facilitating research participation and improving quality of life for African American prostate cancer survivors and their intimate partners. A pilot study of telephone-based coping skills training. Cancer 2007 Jan 15;109(2 Suppl):414-424 [FREE Full text] [CrossRef] [Medline]
    42. Kissane DW, Grabsch B, Clarke DM, Smith GC, Love AW, Bloch S, et al. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. Psychooncology 2007 Apr;16(4):277-286. [CrossRef] [Medline]
    43. Adler NE, Epel ES, Castellazzo G, Ickovics JR. Relationship of subjective and objective social status with psychological and physiological functioning: preliminary data in healthy white women. Health Psychol 2000 Nov;19(6):586-592. [CrossRef] [Medline]
    44. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994 Nov;47(11):1245-1251. [CrossRef] [Medline]
    45. de Souza JA, Yap BJ, Hlubocky FJ, Wroblewski K, Ratain MJ, Cella D, et al. The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer 2014 Oct 15;120(20):3245-3253 [FREE Full text] [CrossRef] [Medline]
    46. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 1997 Mar;15(3):974-986. [CrossRef] [Medline]
    47. Cella D, Hernandez L, Bonomi AE, Corona M, Vaquero M, Shiomoto G, et al. Spanish language translation and initial validation of the functional assessment of cancer therapy quality-of-life instrument. Med Care 1998 Sep;36(9):1407-1418. [CrossRef] [Medline]
    48. Yanez B, Pearman T, Lis CG, Beaumont JL, Cella D. The FACT-G7: a rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research. Ann Oncol 2013 Apr;24(4):1073-1078. [CrossRef] [Medline]
    49. Stanton AL, Bernaards CA, Ganz PA. The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer Inst 2005 Mar 16;97(6):448-456. [CrossRef] [Medline]
    50. Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, PROMIS Cooperative Group. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 2010 Nov;63(11):1179-1194 [FREE Full text] [CrossRef] [Medline]
    51. Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D, PROMIS Cooperative Group. Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger. Assessment 2011 Sep;18(3):263-283 [FREE Full text] [CrossRef] [Medline]
    52. Vickberg SM. The Concerns About Recurrence Scale (CARS): a systematic measure of women's fears about the possibility of breast cancer recurrence. Ann Behav Med 2003;25(1):16-24. [CrossRef] [Medline]
    53. Booth M. Assessment of physical activity: an international perspective. Res Q Exerc Sport 2000 Jun;71(Suppl 2):114-120. [CrossRef] [Medline]
    54. Google Sites. International Physical Activity Questionnaire (IPAQ).   URL: https://sites.google.com/site/theipaq/questionnaire_links [accessed 2019-05-02]
    55. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003 Aug;35(8):1381-1395. [CrossRef] [Medline]
    56. van Poppel MN, Chinapaw MJ, Mokkink LB, van Mechelen W, Terwee CB. Physical activity questionnaires for adults: a systematic review of measurement properties. Sports Med 2010 Jul 1;40(7):565-600. [CrossRef] [Medline]
    57. Wakimoto P. Development and reliability of brief dietary assessment tools for Latinos. Prev Chronic Dis serial online 2006.
    58. Wolf MS, Chang C, Davis T, Makoul G. Development and validation of the Communication and Attitudinal Self-Efficacy scale for cancer (CASE-cancer). Patient Educ Couns 2005 Jun;57(3):333-341. [CrossRef] [Medline]
    59. Jean-Pierre, Fiscella K, Freund KM, Clark J, Darnell J, Holden A, Patient Navigation Research Program Group. Structural and reliability analysis of a patient satisfaction with cancer-related care measure: a multisite patient navigation research program study. Cancer 2011 Feb 15;117(4):854-861 [FREE Full text] [CrossRef] [Medline]
    60. Gruber-Baldini AL, Velozo C, Romero S, Shulman LM. Validation of the PROMIS measures of self-efficacy for managing chronic conditions. Qual Life Res 2017 Jul;26(7):1915-1924 [FREE Full text] [CrossRef] [Medline]
    61. Carver C. Measurement Instrument Database for the Social Sciences. 2006. Measure of Current Status (MOCS).   URL: http://www.midss.org/content/measure-current-status-mocs [accessed 2016-01-08]
    62. Chen JY, Diamant AL, Thind A, Maly RC. Determinants of breast cancer knowledge among newly diagnosed, low-income, medically underserved women with breast cancer. Cancer 2008 Mar 1;112(5):1153-1161 [FREE Full text] [CrossRef] [Medline]
    63. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med 1979 May;41(3):209-218. [CrossRef] [Medline]
    64. Báguena MJ, Villarroya E, Beleña A, Díaz A, Roldán C, Reig R. University of Valencia. Propiedades psicométricas de la versión española de la Escala Revisada de Impacto del Estresor (EIE-R).   URL: https://www.uv.es/baguena/art-IES-R.pdf [accessed 2019-10-10]

    ‎
    BCS: breast cancer survivor
    BCPT: Breast Cancer Prevention Trial
    CASE-cancer: Communication and Attitudinal Self-Efficacy scale for cancer
    CAT: computer adaptive test
    EMR: electronic medical record
    FACT-B: Functional Assessment of Cancer Therapy-Breast
    FACT-G7: Functional Assessment of Cancer Therapy-General
    HRQoL: health-related quality of life
    IRB: institutional review board
    IPAQ: International Physical Activity Questionnaire
    PROMIS: Patient-Reported Outcomes Measurement Information System
    RCT: randomized controlled trial
    REDCap: Research Electronic Data Capture

    Edited by G Eysenbach; submitted 10.04.19; peer-reviewed by M Janda, E Giannoula, C Conley; comments to author 15.06.19; revised version received 09.08.19; accepted 13.08.19; published 13.12.19

    Copyright

    ©Betina R Yanez, Sharon H Baik, Laura B Oswald, Diana Buitrago, Joanna Buscemi, Francisco Iacobelli, Alejandra Perez-Tamayo, Precilla Fajardo, Gabriela Serrano, Judith Guitelman, Frank J Penedo. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 13.12.2019.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.